Thebaine Urine Testing

Recruiting

• Conditions: Urine Specimen Collection

• Registration Number: NCT07192887
• Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Brief Summary

To develop and validate a urine drug screen to detect thebaine.

Detailed Description

Not available

Study Timeline

• Study Start: 2025-05-07
• Study First Submitted: 2025-06-12
• Status Verified: 2025-09
• Study First Submitted QC: 2025-09-17
• Last Update Submitted: 2025-09-17
• Study First Posted: 2025-09-25
• Last Update Posted: 2025-09-25
• Primary Completion: 2027-03
• Study Completion: 2027-03-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Male or female
• Ages 18-65
• Healthy

Exclusion Criteria

• Allergy to poppy seeds, or any of the related food stuffs used in the study
• Celiac disease or gluten sensitivity
• Ongoing or opioid use in the past 6 months
• History of renal or hepatic disease or dysfunction
• Inability or unwillingness to give repeated urine specimens
• Unwillingness to refrain from eating poppy seed-containing products during the two-day course of the study
• Non-English speakers (due to study materials being in English)
• BMI greater than 30
• Antibiotic use in the previous 2 months
• Recent ingestion of poppy seeds from the previous 7 days

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Validate thebaine urine screen	Enrollment to 48 hours after enrollment	Validate a liquid chromatography-tandem mass spectrometry method to detect thebaine in urine

Trial Locations

Locations (1)

Cincinnati Children's Hospital Medical Center; 🇺🇸 Cincinnati, Ohio, United States